The central risk is not demand but conversion: Core Scientific must turn approved and contracted power into live, billable AI capacity before financing costs,
dilution pressure, or customer concentration absorb too much of the value. Texas permissioning, capital intensity, and execution credibility are the real gates between a
rerating and a stalled transition story.